Pioneer in phage-based diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations
Menu
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations

WHO Target Product Profile (TPP) for Tuberculosis

For some of the world's most infectious diseases, such as tuberculosis (TB), The WHO has developed target product profiles (TPPs) to assist developers of new diagnostics.
  • November 14, 2022
  • Phage-based diagnostics
Actiphage journey 2022

The WHO has developed target product profile (TPPs) describing the most appropriate qualities for TB diagnostics and treatments to align their features with the requirements of therapeutic and eradication programmes.

Target product profile for TB

For TB the WHO TPP has the following requirements:

Ease of use – diagnostic must be easy to integrate within existing testing regimes – the sample needs to be accessible with minimal training and to demonstrate the presence of incipient TB.

Cost-effective for rapid screening – diagnostic needs to suitable for rapid screening of asymptomatic patients and perform reliably within given parameters.

Operationally stable – the analysis must be easy to transfer from one lab to another, to have a short number of steps, require minimal training to achieve a result, reagents to be stable within defined temperatures.

To gain a lab side evaluation, Actiphage is currently in trials by the Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network), which is funded by the US National Institutes of Health, at a clinical site in the Philippines. This will give an independent assessment of its usability and fit with the target product profile.

More information about WHO TPP

  1. Development of a Target Product Profile (TPP) and a framework for evaluation for a test for predicting progression from tuberculosis infection to active disease
Actiphage journey 2022 -  meeting WHO target product profile
Share:

Related posts

Loading...
Global Plan to End TB cost of inaction

Improved diagnostics priority in Global Plan to End TB

November 21, 2022
The Global Plan to End TB is a costed public health plan. It aims to cut deaths by 90% in 8 years. A key recommendation of the report is to universally replace sputum microscopy with rapid molecular diagnostics.
Global Plan to End TB cost of inaction

Improved diagnostics priority in Global Plan to End TB

November 21, 2022
The Global Plan to End TB is a costed public health plan. It aims to cut deaths by 90% in...
Five categories of TB

Who is most at risk of developing TB?

November 14, 2022
Tuberculosis (TB) is a bacterial infection that is spread by inhaling tiny droplets in the air released when an infected person coughs or sneezes. Many people carry the disease without realising, creating a reservoir of disease in a population.
Five categories of TB

Who is most at risk of developing TB?

November 14, 2022
Tuberculosis (TB) is a bacterial infection that is spread by inhaling tiny droplets in the air released when an infected...

developers of phage-based diagnostics

Contact Us
BIVDA member 2023

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!